SMN1 and proximal spinal muscular atrophy: In 2019, onasemnogene abeparvovec (OA; ZOLGENSMA®), a single-infusion, adeno-associated virus vector–based gene therapy that delivers a functional copy of SMN1 to motor neurons, was approved to treat children aged < 2 years with SMA [5].